Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chronic lymphocytic leukem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma
• Nodal Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• Kappa CAR T cells co-expressing kappa and CD28 CARs

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Mantle Cell Lymphoma, Follicular Lymphoma | Phase 1 | Status: RECRUITING